Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-Human, Open-Label, Dose Escalation Study of ZL- 1211 in Patients With Unresectable or Metastatic Solid Tumor

NCT05065710 is registered in ClinicalTrials.gov with Zai Biopharmaceutical (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT05065710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-Human, Open-Label, Dose Escalation Study of ZL- 1211 in Patients With Unresectable or Metastatic Solid Tumor
Lead sponsor
Zai Biopharmaceutical (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 19, 2022
Completion date
April 9, 2024
Enrollment
34 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor